El Fadili Mohamed, Er-Rajy Mohammed, Mujwar Somdutt, Ajala Abduljelil, Bouzammit Rachid, Kara Mohammed, Abuelizz Hatem A, Er-Rahmani Sara, Elhallaoui Menana
LIMAS Laboratory, Faculty of Sciences Dhar El Mahraz, Sidi Mohamed Ben Abdellah University, Fez, 30000, Morocco.
Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, 140401, India.
BMC Chem. 2024 Jul 31;18(1):142. doi: 10.1186/s13065-024-01248-6.
Based on a structural family of thirty-two NR2B-selective N-Methyl-D-Aspartate receptor (NMDAR) antagonists, two phenylpiperazine derivatives labeled C37 and C39 were conceived thanks to molecular modeling techniques, as novel NMDAR inhibitors exhibiting the highest analgesic activities (of pIC order) against neuropathic pain, with excellent ADME-toxicity profiles, and good levels of molecular stability towards the targeted protein of NMDA receptor. Initially, the quantitative structure-activity relationships (QSARs) models were developed using multiple linear regression (MLR), partial least square regression (PLSR), multiple non-linear regression (MNLR), and artificial neural network (ANN) techniques, revealing that analgesic activity was strongly correlated with dipole moment, octanol/water partition coefficient, Oxygen mass percentage, electronegativity, and energy of the lowest unoccupied molecular orbital, whose the correlation coefficients of generated models were: 0.860, 0.758, 0.885 and 0.977, respectively. The predictive capacity of each model was evaluated by an external validation with correlation coefficients of 0.703, 0.851, 0.778, and 0.981 respectively, followed by a cross-validation technique with the leave-one-out procedure (CVLOO) with Q of 0.785, more than Y-randomization test, and applicability domain (AD), in addition to Fisher's and Student's statistical tests. Thereafter, ten novel molecules were designed based on MLR QSAR model, then predicted with their ADME-Toxicity profiles and subsequently examined for their similarity to the drug candidates. Finally, two of the most active compounds (C37 and C39) were chosen for molecular docking and molecular dynamics (MD) investigations during 100 ns of MD simulation time in complex with the targeted protein of NMDA receptor (5EWJ.pdb).
基于一个由32种NR2B选择性N - 甲基 - D - 天冬氨酸受体(NMDAR)拮抗剂组成的结构家族,借助分子建模技术构思出了两种标记为C37和C39的苯基哌嗪衍生物,作为新型NMDAR抑制剂,它们对神经性疼痛表现出最高的镇痛活性(pIC级),具有优异的药代动力学 - 毒性特征,并且对NMDA受体的靶向蛋白具有良好的分子稳定性。最初,使用多元线性回归(MLR)、偏最小二乘回归(PLSR)、多元非线性回归(MNLR)和人工神经网络(ANN)技术建立了定量构效关系(QSAR)模型,结果表明镇痛活性与偶极矩、辛醇/水分配系数、氧质量百分比、电负性以及最低未占分子轨道能量密切相关,所生成模型的相关系数分别为:0.860、0.758、0.885和0.977。通过外部验证评估每个模型的预测能力,相关系数分别为0.703、0.851、0.778和0.981,随后采用留一法(CVLOO)交叉验证技术,Q值为0.785,超过Y随机化检验和适用域(AD),此外还进行了费舍尔和学生统计检验。此后,基于MLR QSAR模型设计了10种新型分子,然后预测它们的药代动力学 - 毒性特征,并随后检查它们与候选药物的相似性。最后,选择两种活性最高的化合物(C37和C39)在与NMDA受体的靶向蛋白(5EWJ.pdb)复合的情况下进行100 ns的分子动力学(MD)模拟时间的分子对接和分子动力学(MD)研究。